IP Attys Back Regeneron Over Inequitable Conduct Finding
Numerous intellectual property law organizations and lawyers are calling for the full Federal Circuit to review its panel decision affirming that a Regeneron Pharmaceuticals Inc. patent is unenforceable in part because...To view the full article, register now.
Already a subscriber? Click here to view full article